Evaluation of the immunogenicity and safety of a booster dose of Pfizer's 13-valent pneumococcal conjugate vaccine in children primed with 3 doses of either GSK's 10-valent pneumococcal conjugate vaccine or Pfizer's 13-valent pneumococcal conjugate vaccine in the Czech Republic. [Vyhodnoceni imunogenity a bezpecnosti posilovaci davky 13valentni pneumokokove konjugovane vakciny firmy Pfizer u deti po zakladnim schematu ockovani 3 davkami 10valentni pneumokokove konjugovane vakciny firmy GSK nebo 13valentni pneumokokove konjugovane vakciny firmy Pfizer v Ceske republice]

Trial Profile

Evaluation of the immunogenicity and safety of a booster dose of Pfizer's 13-valent pneumococcal conjugate vaccine in children primed with 3 doses of either GSK's 10-valent pneumococcal conjugate vaccine or Pfizer's 13-valent pneumococcal conjugate vaccine in the Czech Republic. [Vyhodnoceni imunogenity a bezpecnosti posilovaci davky 13valentni pneumokokove konjugovane vakciny firmy Pfizer u deti po zakladnim schematu ockovani 3 davkami 10valentni pneumokokove konjugovane vakciny firmy GSK nebo 13valentni pneumokokove konjugovane vakciny firmy Pfizer v Ceske republice]

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Dec 2014

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Acronyms PCV-MIXED-SCHEDULE
  • Most Recent Events

    • 13 Dec 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 20 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top